Login
$CERO
$0.10 +$0.00 (0.0%) Close

$CERO 8-K SEC Filings

Filed On Filing
07 Oct 2026 8-K: Entry into a Material Definitive Agreement

This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of October 6, 2026, is made by and among CERo Therapeutics Holdings, Inc., a Delaware corporation (“Seller”), and SRX Global Inc., a Delaware corporation formerly known as SRX He...

31 Aug 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT...

17 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

26 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

29 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Healt...

01 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keysto...

14 Apr 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keyston...

11 Mar 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone...

13 Feb 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more

NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT O F 1933, AS AME NDE D (THE “ 1933 ACT”), OR ANY U.S. STATE. SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDI...

04 Feb 2026 8-K: Other Events

CER - 1236 is a first - in - class chimeric antigen receptor T - cell (CAR - T) therapy designed to induce phagocytic target clearance through a TIM - 4 – based receptor ectodomain. TIM - 4 targets TIM - 4 - L, or phosphatidylserine, a s...

03 Feb 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on October 29, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received the determination from the Nasdaq Hearing Panel (the “Panel”) to delist the securities of the Company from t...

07 Jan 2026 8-K: Regulation FD Disclosure; Other Events

CERO This presentation (this “Presentation”) is provided for informational purposes only and for no other purpose and has been prepared to assist interested parties in making their own evaluation with respect to a potential investment in...

19 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

This Amendment to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (“Amendment”) is hereby adopted by the Board of Directors (the “Board”) of CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”). All ca...

02 Dec 2025 8-K: Entry into a Material Definitive Agreement

This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of November 26, 2025 (this “Agreement”), by and among Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and CERo Therapeutics Holdings,...

30 Oct 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

16 Oct 2025 8-K: Entry into a Material Definitive Agreement; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE...

14 Oct 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE...

22 Sep 2025 8-K: Regulation FD Disclosure

NASDAQ: CERO This presentation (this “Presentation”) is provided for informational purposes only and for no other purpose and has been prepared to assist interested parties in making their own evaluation with respect to a potential inves...

05 Sep 2025 8-K: Other Events

Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program

04 Sep 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support